Sector-wide pullbacks in pharmaceutical equities are frequently triggered by regulatory tightening, pricing scrutiny in key domestic and international markets, patent cliff expirations, and the high cost of transitioning capital toward complex biologic drugs. Additionally, sector rotation by institutional investors moving capital into high-growth technology industries during shifting macroeconomic cycles can place temporary downward pressure on healthcare stock valuations despite stable underlying demand.